Sapanisertib

Sapanisertib (also known as MLN0128, INK128 and TAK-228) is an experimental small molecule inhibitor of mTOR which is administered orally. It targets both mTORC1 and mTORC2.^[1]

Sapanisertib

Identifiers
IUPAC name 5-(4-Amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine
CAS Number	1224844-38-5
PubChem CID	45375953
UNII	JGH0DF1U03
KEGG	D11183
ChEBI	CHEBI:91450
CompTox Dashboard (EPA)	DTXSID401022538
Chemical and physical data
Formula	C15H15N7O
Molar mass	309.333 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)N1C2=C(C(=N1)C3=CC4=C(C=C3)OC(=N4)N)C(=NC=N2)N
InChI InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19) Key:GYLDXIAOMVERTK-UHFFFAOYSA-N

Developed by Millennium Pharmaceuticals,^[2][3][4] and is in phase II clinical trials for breast cancer, endometrial cancer, glioblastoma, renal cell carcinoma, and thyroid cancer.^[5] The drug has been well tolerated by patients with advanced solid tumours in Phase I trials.^[6]